Business Context and Reporting Period
Company: NextCure, Inc. (NXTC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: NextCure is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer patients who have not responded to current therapies. The company's primary pipeline consists of two lead candidates: SIM0505 (targeting CDH6) and LNCB74 (targeting B7-H4). In March 2024, the company executed a restructuring to prioritize these programs, pausing internal manufacturing operations and reducing its workforce.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(55.8) million | $(55.7) million |
| Operating Expenses | $57.6 million | $59.7 million |
| Cash, Cash Equivalents & Marketable Securities | $41.8 million | $68.6 million |
| Accumulated Deficit | $(436.0) million | $(380.1) million |
| Net Cash Used in Operating Activities | $(49.6) million | $(40.8) million |
| Net Cash Provided by Financing Activities | $22.3 million | $0.1 million |
Note: The company has no debt obligations listed in the balance sheet liabilities section, consisting primarily of lease liabilities and accrued expenses.
Material Changes vs. Prior Period
- Research and Development (R&D) Expenses: Increased by $3.4 million (8%) to $44.9 million. This increase was driven primarily by $20.4 million in costs associated with the new SIM0505 program, including $18.5 million in license fees and milestone payments to Simcere Zaiming Pharmaceutical Co., Ltd. (Zaiming). These costs were partially offset by reduced spending on other deprioritized programs (NC410 and NC525) and lower internal personnel costs.
- General and Administrative (G&A) Expenses: Decreased by $3.0 million to $12.7 million, primarily due to lower personnel-related costs ($2.5 million reduction) and reduced insurance expenses.
- Restructuring Charges: The company incurred $2.5 million in restructuring and asset impairment charges in 2024 related to a workforce reduction and manufacturing pause. No such charges were recorded in 2025.
- Liquidity: Cash and marketable securities decreased from $68.6 million in 2024 to $41.8 million in 2025, reflecting operating burn and capital deployment for the SIM0505 license.
Guidance, Outlook, and Risks
Outlook and Guidance
- Runway: Management expects current cash resources ($41.8 million) to fund operations into the first half of 2027. However, the company has stated there is substantial doubt regarding its ability to continue as a going concern for a period of one year after the issuance of the financial statements without additional financing.
- Clinical Milestones:
- SIM0505: First patient dosed in the U.S. in October 2025. Phase 1 dose escalation data readout is expected in Q2 2026.
- LNCB74: First patient dosed in January 2025. Proof of concept data readout has been updated to the second half of 2026 to accommodate expanded dosing and enrollment.
- Capital Needs: The company anticipates needing substantial additional funding to advance clinical programs beyond the first half of 2027. Failure to secure funding may result in further cost-cutting, program delays, or termination.
Key Risks and Contingencies
- Going Concern: The company has a history of significant losses and an accumulated deficit of $436.0 million. It requires immediate additional funding to continue operations as planned.
- Manufacturing: Internal manufacturing operations were paused in March 2024. The company relies on third-party contract manufacturing organizations (CMOs), including WuXi XDC, which faces potential restrictions under the U.S. BIOSECURE Act signed into law in December 2025.
- Regulatory and Clinical: As a clinical-stage company with no approved products, success depends on the uncertain outcomes of clinical trials and regulatory approvals. Small sample sizes in Phase 1 trials may limit the reliability of early data.
- Intellectual Property: The company relies on licensed IP from Yale University and Zaiming. Breach of these agreements could terminate rights to key product candidates.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the company's efforts to raise additional capital to extend its runway beyond the first half of 2027, given the "substantial doubt" going concern warning.
- License Agreement Obligations: Review the specific payment terms and milestone triggers in the June 2025 License Agreement with Zaiming, particularly the $17 million upfront/short-term payment structure and future milestone obligations.
- Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act on the company's reliance on WuXi XDC for conjugating LNCB74 and the availability of alternative CMOs.
- Clinical Trial Progress: Monitor the Q2 2026 data readout for SIM0505 and the H2 2026 update for LNCB74 for safety and efficacy signals.
- Stock Dilution: Note the November 2025 private placement and the December 2025 establishment of a new "at-the-market" (ATM) offering agreement, which may lead to further dilution.